Compare TISI & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TISI | IMA |
|---|---|---|
| Founded | 1973 | 2019 |
| Country | United States | United States |
| Employees | 6800 | 17 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.3M | 66.3M |
| IPO Year | 1995 | N/A |
| Metric | TISI | IMA |
|---|---|---|
| Price | $16.70 | $5.97 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 3.2K | ★ 8.4K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $896,483,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.19 | N/A |
| 52 Week Low | $12.34 | $3.94 |
| 52 Week High | $19.99 | $17.50 |
| Indicator | TISI | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 47.05 |
| Support Level | $16.62 | $5.36 |
| Resistance Level | $17.10 | $6.13 |
| Average True Range (ATR) | 0.65 | 0.31 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 52.17 | 37.76 |
Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.